Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial.

Seung Young SeoSoo Teik LeeSung Kook KimHoon Jai ChunGeun Am SongDong Ho LeeJae Jun KimJin Il KimYoung Chan LeeTae Nyeun KimSam Ryong JeeSeon-Young ParkJae Gyu KimJong-Jae ParkSang Gyun KimJae Myung ParkJung Ho ParkShin Jung ParkOh Young Lee

Published in: Medicine (2023)

These results demonstrate that CKD-495 75 mg is superior to AAF 60 mg in terms of the endoscopic improvement rate of erosions in patients with acute or chronic gastritis. This new mucoprotective agent, CKD-495, can be considered the therapy of choice for symptomatic relief and healing of gastritis.

Keyphrases

phase iii
helicobacter pylori
clinical trial
helicobacter pylori infection
chronic kidney disease
open label
phase ii
double blind
drug induced
liver failure
ultrasound guided
respiratory failure
study protocol
randomized controlled trial
stem cells
bone marrow
aortic dissection
replacement therapy